[ATL (adult T-cell leukemia/lymphoma)]

Area of Science:

• Hematology
• Oncology
• Virology

Context:

• Adult T-cell leukemia/lymphoma (ATL) is a heterogeneous malignancy with varying clinical presentations and prognoses.
• Understanding subtype-specific survival is crucial for effective patient management and treatment strategies.
• Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent for ATL.

Purpose:

• To evaluate the prognostic differences among acute, chronic, and lymphoma types of ATL.
• To assess the efficacy of cis-dichlorodiammineplatinum (CDDP) in refractory non-Hodgkin's lymphoma, a related condition.
• To explore preventive strategies for reducing future ATL occurrence.

Summary:

• Prognostic evaluation of 128 ATL cases revealed median survival times from onset: acute type (8 months), lymphoma type (14 months), and chronic type (50 months).
• Median survival from treatment start differed: acute type (5 months), lymphoma type (11 months), and chronic type (22 months).
• Combination therapy with CDDP showed promising response rates (4 complete, 6 partial remissions) in 10 evaluable patients with refractory non-Hodgkin's lymphoma.

Impact:

• The findings highlight significant survival disparities among ATL subtypes, emphasizing the need for tailored treatment approaches.
• The study suggests that preventing transmission of HTLV-1 from carrier mothers to their children could be an effective strategy to decrease future ATL incidence.
• CDDP-based chemotherapy demonstrates potential utility in managing specific refractory lymphoma cases.